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Abstract The extracellular moiety of the hemoglobin/haptoglo-
bin scavenger receptor CD163 (RM3/1 antigen) can be shed
from monocytes and is a normal plasma component. We found
that in a dose-dependent manner soluble CD163 induces a de-
crease in CD69 expression, a reduced [3H]thymidine uptake and
a down-regulated matrix metalloproteinase-9 RNA expression
in phorbol myristate acetate-stimulated T-cells. Co-culturing
T-cells on transgenic ¢broblasts, expressing membrane-bound
CD163, yielded no di¡erences compared to culture on non-
transfected cells. We conclude that CD163 has at least two
distinct functions: the clearance of hemoglobin in its cell-bound
form and participation in anti-in£ammation as a soluble factor,
exhibiting cytokine-like functions. 1 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
CD163, previously described as RM3/1 antigen or M130,
belongs to the cysteine-rich scavenger receptor superfamily
type B and has recently been identi¢ed as a receptor for the
hemoglobin/haptoglobin complex [1]. Earlier observations
have linked the expression of CD163 on monocytes to anti-
in£ammatory functions. In vitro, CD163 can be up-regulated
by glucocorticoids and interleukin-10 [2,3], whereas proin-
£ammatory stimuli like lipopolysaccharide or interferon-Q
suppress its expression [2,4]. In vivo, CD163-positive macro-
phages are found during the late phase of acute in£ammation
[5] as well as in chronic in£ammation [6] and in wound heal-
ing tissue [7]. CD163-positive monocytes were also shown to
inhibit proliferation of CD4-positive T-lymphocytes (TL) in
co-culture [8], however, nothing is known about a direct par-
ticipation of CD163 in this process. Another not further char-
acterized anti-in£ammatory factor has been described to be
secreted by CD163-positive monocytes [9] as well as increased
amounts of histamine [10]. Therefore it is still an open ques-
tion whether expression of CD163 represents just a certain
anti-in£ammatory phenotype, or the cell-bound molecule di-
rectly contributes to anti-in£ammatory e¡ects. Recently, it
was shown that CD163 can be shed from the cell membrane
of glucocorticoid-stimulated monocytes [11] after an in£am-
matory stimulus and that CD163 is a normal component in
the plasma of healthy donors [12,13]. In addition, soluble
CD163 has been shown to inhibit phorbol ester-induced pro-
liferation of TL [14].
In this study we show that soluble CD163 acts anti-in£am-
matory on transcription, surface marker gene expression and
growth of phorbol myristate acetate (PMA)-stimulated
T-cells, whereas the membrane-bound form has no e¡ect.
This is the ¢rst evidence that a scavenger receptor can have
cytokine-like functions and implicates distinct functions for
the membrane-bound and shedded protein.
2. Materials and methods
2.1. Construction of CD163-expressing HEK cells
The cDNA of CD163 was obtained by reverse transcription (RT)-
PCR with primers spanning nt 81^103 and 3194^3215 of the pub-
lished mRNA sequence [15] with attached recognition sites for SalI
(forward primer) and XhoI (reverse primer). It was then cloned into
pBK-CMV (Stratagene) and sequenced (Sequenase 2.0 kit, Amer-
sham). 15 Wg of linearized DNA was transfected into 107 HEK293
cells by electroporation (pulse 290 V, 950 WF, 40 s), transfected cells
were selected with 500 Wg/ml G418 for 10 passages. CD163 expression
was £uorescence-activated cell sorter (FACS)-analyzed with the
monoclonal antibody RM3/1 (our lab) and a FITC-labeled goat
anti-mouse antibody (Dianova).
2.2. CD163-containing supernatant and puri¢cation of cellular CD163
CD163 was puri¢ed from lysates of £uticasone propionate (FP)-
stimulated monocytes by a⁄nity columns with the monoclonal anti-
body RM3/1 as described elsewhere [11]. Purity was controlled by gel
electrophoresis and subsequent silver staining or Western blotting us-
ing the monoclonal antibodies RM3/1 and Ki-M8 (Bachem, Heidel-
berg, Germany), a horseradish peroxidase-conjugated secondary anti-
body (Dako Diagnostics, Hamburg, Germany) and the ECL kit
(Amersham Pharmacia Biotech, Freiburg, Germany) (Fig. 1). Alter-
natively, shedding of CD163 was induced by 1037 M PMA. This
supernatant was then washed three times with phosphate-bu¡ered
saline (PBS) and 10-fold concentrated in a 50 kDa ¢lter unit (Viva-
science).
2.3. Puri¢cation of recombinant CD163
The extracellular moiety of CD163 was ampli¢ed by PCR and
cloned into the expression vector pcDNA6/V5-His (Invitrogen, Karls-
ruhe, Germany). HEK293 cells were transfected as described above,
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the supernatant was investigated by Western blot analysis to con¢rm
the integrity of the recombinant protein. Puri¢cation of the recombi-
nant protein was performed by binding of the carboxy-terminal His-
Tag to Talon1-Matrix, according to the manufacturer’s protocol (BD
Biosciences Clontech, Palo Alto, CA, USA). Purity was then con-
trolled by gel electrophoresis and subsequent silver staining and West-
ern blotting (Fig. 1). Densitometric analysis of both the silver-stained
and the Western blotting bands (Adobe Photo Shop software) showed
a decreased (64%) antibody binding to the recombinant protein, as
compared with the CD163 puri¢ed from cell lysates. This reduced
antibody binding was not observed with non-puri¢ed recombinant
CD163 (not shown) and is therefore probably related to the puri¢ca-
tion protocol, which includes a drastic pH change for elution of the
protein.
2.4. Puri¢cation of TL
T-cells from healthy donors (Blutbank, University of Mu«nster,
Mu«nster, Germany) were puri¢ed from the lymphocyte fraction ob-
tained after Ficoll and subsequent Percoll density gradient centrifuga-
tion. Contaminating monocytes and B-lymphocytes were allowed to
adhere to a nylon matrix as previously described [16], eluted cells were
about 80% CD4-positive and more than 98% CD14-negative as de-
termined by FACS analysis. Cells were always held in RPMI 1640
medium supplemented with 10% fetal calf serum and standard
amounts of antibiotics.
2.5. Inhibition of CD69 expression
5U105 TL were incubated in 96-well plates in the presence of di¡er-
ent concentrations of CD163, either 10% 10-fold concentrated CD163
supernatant, puri¢ed CD163 or recombinant CD163, and PMA (1037
M for 3 h or 108 M for 20 h). If indicated, the monoclonal antibody
RM3/1 was supplemented at a concentration of 2.5 Wg/ml. CD69
expression was determined by FACS with a FITC-conjugated anti-
body (Dako Diagnostics, Hamburg, Germany). For co-culture experi-
ments 106 TL were incubated on s 95% con£uent HEK cells (pre-
treated with 100 Wg/ml mitomycin C for 3 h) in 24-well plates. The
increases of £uorescence were calculated by subtracting the values of
non-stimulated cells, using the Lysis-II software. Mean values of mul-
tiple independent experiments (nv 3) were then statistically analyzed,
signi¢cance in this study was always con¢rmed by a Student’s t-test.
2.6. Proliferation assay
Proliferation of activated TL was determined by incorporation of
tritium-labeled thymidine. 5U105 TL were incubated with 1039 M
PMA, 1038 M FP and di¡erent concentrations of CD163 and the
monoclonal antibody RM3/1, as indicated, for 43 h. In a pre-experi-
ment 1039 M PMA had shown to be su⁄cient to initiate proliferation
of TL under these conditions. Then 1 WCi of [3H]thymidine was
added. After 5 h the cells were harvested, washed with PBS three
times and lysed by three freeze/thaw cycles. Counts per minute were
then determined in a scintillation counter. For co-cultivation HEK
cells were pre-treated as described above.
2.7. Semi-quantitative RT-PCR
PCR conditions and primers were taken from Giambernadi et al.
[17]. Brie£y, 2U105 TL were incubated with PMA, FP (1038 M each)
and di¡erent concentrations of CD163, as indicated, for 24 h. Then
total RNA was extracted with the RNeasy kit (Qiagen, Hilden) ac-
cording to the manufacturer’s instructions. 500 ng of RNA was re-
verse-transcribed (Superscript, Gibco, volume 20 Wl), 6 Wl was then
used as template for a 120 Wl PCR mix, which was divided into six
20 Wl probes. From cycle 15 on one probe was taken out of the cycler
every ¢ve cycles and analyzed by agarose gel electrophoresis.
3. Results and discussion
Expression of CD69 is accepted as an early marker for
qualitative and quantitative analysis of TL activation [18].
Fig. 2 shows the proportional increase in CD69 expression
after stimulation of TL with PMA and the inhibition by solu-
ble CD163. CD163-containing supernatant of FP-stimulated,
washed, and PMA-treated monocytes was used after diluting
and concentrating the solution to eliminate the PMA. The
mean inhibition was 29.4%. To exclude the in£uence of con-
taminants, antibody-puri¢ed CD163 at a concentrations of 0.1
and 0.5 Wg/ml as well as recombinant CD163 at a concentra-
tion of 0.5 Wg/ml were used in the same assay and exhibited a
mean inhibition of 15.6, 23.6 and 9.3%, respectively. Addition
of the monoclonal antibody RM3/1 (2.5 Wg/ml) reduced the
e¡ect of the CD163-containing supernatant from 29.4 to
8.3%. Although stimulation with 1037 M PMA for 3 h gen-
erally yielded lower CD69 expression than with 1038 M PMA
for 20 h, the relative inhibition by CD163 was in the same
range. The fact that the recombinant CD163 did not yield as
striking e¡ects as the puri¢ed CD163 from cell lysates might
be related to the observation that there is a reduced antibody
binding to the recombinant CD163 after puri¢cation (see Ma-
terials and methods). The puri¢cation procedure includes a
pH 5.5 step to elute the protein from the matrix, this might
have modi¢ed the structure of the protein. Therefore, the
recombinant protein was not used in further experiments.
To elucidate the question if membrane-bound CD163 has
the same e¡ect, HEK293 cells were stably transfected with the
vector pBK-M130. After selection with G418 for 10 passages
we received a population of cells expressing similar amounts
up to 10-fold more CD163 as FP-stimulated monocytes, as
determined by FACS analysis (data not shown). The last two
bars of Fig. 2 show that co-culturing of PMA-stimulated TL
with these CD163-expressing HEK cells yields no di¡erence in
CD69 expression, compared to co-culture with non-trans-
fected cells.
To con¢rm the inhibitory e¡ect of solely the soluble form of
CD163 we investigated the thymidine uptake of TL after
PMA stimulation (Fig. 3a). Similar to the previous results,
TL activation is suppressed in a concentration-dependent
manner: CD163 in a concentration of 0.1 Wg/ml leads to a
slight but not signi¢cant inhibition (Ps 0.1), whereas the in-
crease of thymidine uptake after PMA stimulation in the pres-
ence of 0.5 Wg/ml CD163 is diminished to 61% (P6 0.05).
Although this e¡ect is not as dramatic as the suppression
observed by addition of FP (a reduction to 17.6%), it can
be partly reversed by adding 2.5 Wg/ml RM3/1 (81.7%) and
thus con¢rms the inhibitory impact of CD163 on activated
TL.
Fig. 3b shows that no di¡erence in thymidine uptake is
observable when seeding PMA-stimulated TL on CD163-
transfected or untransfected HEK cells. Although the HEK
cells were mitomycin-treated, they still showed some thymi-
dine incorporation, with no di¡erence between transfected
and non-transfected cells. FACS analysis during the experi-
ments con¢rmed stable CD163 expression under the experi-
mental conditions (not shown). During the co-culture 20^30%
of the feeder cells were killed (as determined by propidium
iodide staining), however, no CD163 was shed from the cells
and could be identi¢ed in the medium by Western blotting
(not shown).
These data show that the inhibitory e¡ect is limited to the
soluble form of CD163. Membrane-anchored protein has no
e¡ect in this study, although it can mediate hemoglobin/hap-
toglobin incorporation as shown before [1]. Therefore, the
previous observation that CD163-positive monocytes inhibit
the proliferation of activated TL [8] is probably triggered by
factors which are associated with the CD163-positive pheno-
type and not with the membrane-bound CD163 itself. The
observed signi¢cant but low inhibition of TL activation by
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soluble CD163 also suggests a synergistic e¡ect together with
other factors. Together with the previous observation that
in£ammatory stimuli induce the shedding of CD163, we pro-
pose the following model: in the late phase of an in£amma-
tion, CD163-positive macrophages migrate to the correspond-
ing tissue. Once they have contact to in£ammatory factors,
the CD163 is shed to act synergistically with other mediators
of anti-in£ammation. In the intercellular space the concentra-
tion of CD163 should be high enough to mediate certain
functions in the present, in£ammatory primed, T-cells and
help to restore the normal, healthy conditions.
As soluble CD163 is a normal plasma protein, its function
there might also be to suppress TL and take part in the reg-
ulation of immune responses under healthy conditions. To
investigate this, we measured the RNA expression of gelatin-
ases, which are necessary for transmigration through vessel
walls [19]. The gelatinase matrix metalloproteinase (MMP)-9
is constitutively expressed in TL with an enhanced expression
during activation of the cells [20]. In contrast, MMP-2 needs
adherence of TL to endothelial cells to be expressed, but is up-
regulated by monocytes/macrophages after in£ammatory
stimuli and is therefore suitable as a control for the purity
of the investigated TL [21,22]. We performed a semi-quanti-
tative RT-PCR for these transcripts after PMA stimulation
and found a concentration-dependent inhibition of MMP-9
expression, mediated by CD163 (Table 1). Even the lower
concentration (0.1 Wg/ml) mediated the same gene expression
as the anti-in£ammatory glucocorticoid FP. CD163 alone
Fig. 1. Analysis of puri¢ed CD163 with silver staining (top) and
Western blotting (bottom). M: Marker. 1: CD163 puri¢ed from cell
lysates. 2: Recombinant CD163 after Talon puri¢cation. Although
the intensity of band 1 is lower after silver staining, compared with
2, it is stronger in the Western blot analysis.
Fig. 2. Inhibition of CD69 expression on PMA-activated TL by
soluble CD163. TL were stimulated with 1037 M PMA for 3 h and
1038 M for 20 h in the presence of either CD163-containing super-
natant ( R the monoclonal antibody RM3/1) from FP-stimulated
monocytes after PMA-induced shedding, two di¡erent concentra-
tions of puri¢ed CD163 from monocyte lysates or recombinant
CD163. The mean increase in CD69 expression, determined by
FACS analysis, after PMA stimulation alone in comparison to un-
stimulated cells is de¢ned as 100% (T-L). The last two bars show
the CD69 expression on CD163-expressing or native HEK293 cells
after PMA stimulation. Sup: Supernatant, RM: RM3/1 2.5 Wg/ml,
CD163 0,1/0,5: 0.1 or 0.5 Wg/ml, rec CD163: recombinant CD163
0.5 Wg/ml.
Fig. 3. Reduction of thymidine incorporation into PMA-activated
TL is mediated solely by soluble CD163. TL were incubated for
2 days with 1039 M PMA and (a) di¡erent concentrations of puri-
¢ed CD163 or (b) co-cultured on native or CD163-expressing, mito-
mycin-treated HEK293 cells. Cells were chased with [3H]thymidine
and analyzed in a scintillation counter. T-L: T-lymphocytes, cpm:
counts per minute, 0,1/0,5: 0.1 or 0.5 Wg/ml, RM: monoclonal anti-
body RM3/1, FP: £uticasone propionate.
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(0.5 Wg/ml), which was used as a control without PMA, was
able to reduce the basic MMP-9 expression to a level which
was hardly detectable by this method. MMP-2 expression
could not be observed in our assay, indicating the absence
of contaminating macrophages in the samples. The normal
level of soluble CD163 in plasma has recently been shown
to be in the range of 0.7^4.69 Wg/ml [13]. Thus, the here
observed dose-dependent e¡ects might be even more distinct
under natural conditions. However, this remains speculative,
as further experiments with higher concentrations could not
be performed due to limiting amounts of puri¢ed CD163.
In this study we show that the hemoglobin scavenger re-
ceptor CD163 also has cytokine-like functions, which have
never been described for a scavenger receptor before. How-
ever, sequencing and analysis of the human genome [23]
pointed out that there are fewer genes existing than estimated
before. Therefore, it seems not unlikely that certain gene
products can have a tremendously variable function. Probably
many more of such diverse functions of a unique gene product
will be observed in the future.
As only soluble CD163 has an inhibitory function on the
activation of TL, it is likely that TL have a speci¢c receptor
which mediates the uptake of CD163, as binding to the re-
ceptor alone on transfected, CD163-expressing cells initiates
no signal. Identi¢cation of this receptor would be of great
help to understand the intracellular reactions in TL mediated
by CD163, and further studies will have to show how CD163
¢ts into the existing network of the numerous in£ammatory
and anti-in£ammatory factors.
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Table 1
Down-regulation of MMP-9 expression by CD163
Distinct band after cycle number
L-Actin MMP-2 MMP-9 Rating
TL 20 ^ 35 ++
TL+PMA 20 ^ 30 +++
TL+PMA+FP 20 ^ 35 ++
TL+PMA+CD163 0.1 Wg/ml 20 ^ 35 ++
TL+PMA+CD163 0.5 Wg/ml 20 ^ 40 +
TL+CD163 0.5 Wg/ml 20 ^ (40) slight band (+)
TL were incubated in the presence of PMA and FP (1038 M each) or di¡erent concentrations of CD163. A semi-quantitative RT-PCR was
performed with probes for L-actin and MMP-2 as controls.
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